Abstract C50: Phase I dose escalation study of the oral multi-kinase VEGF inhibitor regorafenib and the anti-EGFR monoclonal antibody cetuximab in patients with advanced solid tumors including colorectal cancer
Conclusions: The combination of cetuximab and regorafenib was well tolerated at doses of cetuximab IV 200 mg/m2 followed by 150 mg/m2 weekly, with regorafenib 80 mg daily. Anticancer activity was observed in patients with wild type colorectal cancer.Citation Format: Vivek Subbiah, David S. Hong, Behrang Amini, Sarina Piha-Paul, Joanna Grace Fernandez, Siquing Fu, Apostolia M. Tsimberidou, Aung Naing, Filip Janku, Daniel D. Karp, Michael Overman, Cathy Eng, Scott Kopetz, Funda Meric-Bernstam, Gerald S. Falchook. Phase I dose escalation study of the oral multi-kinase VEGF inhibitor regorafenib and the anti-EGFR monoclonal antibody cetuximab in patients with advanced solid tumors including colorectal cancer. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C50.
Source: Molecular Cancer Therapeutics - Category: Cancer & Oncology Authors: Subbiah, V., Hong, D. S., Amini, B., Piha-Paul, S., Fernandez, J. G., Fu, S., Tsimberidou, A. M., Naing, A., Janku, F., Karp, D. D., Overman, M., Eng, C., Kopetz, S., Meric-Bernstam, F., Falchook, G. S. Tags: Clinical Trials: Poster Presentations - Proffered Abstracts Source Type: research
More News: Bleeding | Cancer | Cancer & Oncology | Carcinoma | Carcinoma of Unknown Primary | Clinical Trials | Colorectal Cancer | Conferences | Erbitux | HNPCC | Hypertension | Kidney Cancer | Lynch Syndrome | Oral Cancer | Renal Cell Carcinoma | Squamous Cell Carcinoma | Study | Thrombocytopenia | Toxicology